Good
Mostly Aligned
Patient Risk:
Low
Summary
Most dosing-frequency and missed-dose instructions match the label, but the H. pylori regimen claims are partially inconsistent with the labeled dosing (triple vs dual therapy require different schedules).
Category Scores
Accurate Statements
Voquezna (vonoprazan) is dosed at 20 mg once daily for acid-related conditions.
Section 2.1: Healing of erosive esophagitis—VOQUEZNA 20 mg once daily for 8 weeks; also indicated for erosive esophagitis/heartburn conditions in adults.
If a dose of Voquezna is missed, it should be taken when the patient remembers.
Section 2.4 Missed doses: administer within 12 hours (healing/maintenance or non-erosive GERD) or within 4 hours (H. pylori); otherwise skip and take next scheduled dose.
If a dose of Voquezna is missed, the patient should not take extra doses to make up for the missed dose.
Section 2.4 Missed doses: if more than 12 hours (or 4 hours for H. pylori) have passed, skip and administer next dose at regularly scheduled time (i.e., do not take an extra/makeup dose).
Unsupported Statements
For H. pylori treatment regimens, Voquezna is taken as 20 mg once daily together with the antibiotics prescribed in that regimen.
Section 2.1 specifies different labeled VOQUEZNA dosing schedules for H. pylori regimens: triple therapy is VOQUEZNA 20 mg plus antibiotics each given twice daily; dual therapy is VOQUEZNA 20 mg given twice daily (not once daily) with amoxicillin three times daily. The claim generalizes to 20 mg once daily, which is not supported as the labeled regimen dosing.
Contradictions
Low
AI Statement
For H. pylori treatment regimens, Voquezna is taken as 20 mg once daily together with the antibiotics prescribed in that regimen.
Label Reference
Section 2.1 Treatment of H. pylori infection: Triple Therapy—VOQUEZNA 20 mg given twice daily; Dual Therapy—VOQUEZNA 20 mg given twice daily. (Also clarifies dosing schedule alignment with antibiotics.)
Important Omissions
For missed doses, the label requires regimen/indication-specific windows (within 12 hours for erosive esophagitis/maintenance or non-erosive GERD; within 4 hours for H. pylori) and explicitly instructs skipping if the window is exceeded.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Primary potential issue is the H. pylori regimen dosing claim (once-daily vs twice-daily per label), which could lead to underdosing relative to labeled regimen schedules. Missed-dose statements are broadly consistent with label intent but omit the indication-specific time windows.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
H. pylori dosing: claim that Voquezna 20 mg is taken once daily with antibiotics is inconsistent with label (VOQUEZNA is twice daily in both labeled triple and dual therapies; antibiotics have their own specific schedules).
Suggested Improvement
Revise the H. pylori claim to reflect labeled regimens: Triple therapy—VOQUEZNA 20 mg + amoxicillin 1000 mg + clarithromycin 500 mg, each twice daily for 14 days; Dual therapy—VOQUEZNA 20 mg twice daily with amoxicillin 1000 mg three times daily for 14 days. Also include the missed-dose windows (12 hours vs 4 hours) by indication.